{"altmetric_id":4690916,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["SCRI Development Innovations, LLC"],"first_seen_on":"2015-10-28T13:59:35+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1416237666,"links":["http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02291913?term=metastatic+breast+cancer&amp%3Brcv_d=14&amp%3Bshow_rss=Y"],"nct_id":"NCT02291913","pubdate":"2014-11-10T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer","type":"clinical_trial_study_record"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":4518162,"mean":5.2825433907977,"rank":3662561,"this_scored_higher_than_pct":3,"this_scored_higher_than":138463,"rank_type":"exact","sample_size":4518162,"percentile":3},"similar_age_3m":{"total_number_of_other_articles":116516,"mean":7.6012134231644,"rank":87451,"this_scored_higher_than_pct":1,"this_scored_higher_than":1717,"rank_type":"exact","sample_size":116516,"percentile":1},"this_journal":{"total_number_of_other_articles":11235,"mean":3.1818557949083,"rank":9369,"this_scored_higher_than_pct":2,"this_scored_higher_than":282,"rank_type":"exact","sample_size":11235,"percentile":2},"similar_age_this_journal_3m":{"total_number_of_other_articles":392,"mean":2.316,"rank":323,"this_scored_higher_than_pct":1,"this_scored_higher_than":2,"rank_type":"exact","sample_size":392,"percentile":1}}},"demographics":[],"counts":{"total":{"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["348416685235849"],"posts_count":1}},"posts":{"facebook":[{"title":"Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer","url":"https:\/\/www.facebook.com\/348416685235849\/posts\/715315581879289","license":"public","citation_ids":[4690916],"posted_on":"2014-11-17T15:21:06+00:00","summary":"Condition: Breast Cancer\nInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Tamoxifen; Drug: Fulvestrant; Drug: Anastrozole; Drug: Letrozole; Drug: Toremifine\nSponsors: SCRI Development Innovations, LLC; Novartis\nNot yet recruiting - verified \u2026","author":{"name":"Metastatic Breast cancer News","url":"https:\/\/www.facebook.com\/348416685235849","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/348416685235849\/picture","id_on_source":"348416685235849"}}]}}